Hemanext is a Lexington, MA–based medical technology company dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. Led by CEO Martin Cannon, the company’s R&D centers on the study and application of hypoxically stored red blood cells (RBCs). Its HEMANEXT ONE system limits O2 and CO2 levels in the storage environment and is CE Marked in Europe for processing and storage of CPD/PAGGSM leukocyte‑reduced RBCs prepared within 24 hours of collection. The company raised $18m in Series B equity funding and intends to use the proceeds to accelerate growth and expand operations and business reach. To date Hemanext has raised approximately $130m in total funding, inclusive of $8m in grant funding from the National Institutes of Health. The company plans to keep the current Series B open for a few weeks and expects to begin a Series C with institutional investors in 2023.

Total raised

$18M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2022